Bolstering a specific enzyme within the mitochondria of intestinal cells helped mitigate GI disease induced by T cells after bone marrow transplant, cancer immunotherapy.

In a clinical trial, adding interferon treatment with a bone marrow transplant bolstered outcomes for patients with advanced, high-risk leukemia.

While it plays a protective role in other diseases, knocking out NLRP6 in mice led to better outcomes, less-severe symptoms after bone marrow transplant.

In a new study, researchers looked for alterations in the gut microbiome to see whether its metabolites could improve outcomes after bone marrow transplants.